These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability. Nolan S, Arnason T, Drucker A, Huang WY. Appl Immunohistochem Mol Morphol; 2014; 22(5):e8-e13. PubMed ID: 24805134 [Abstract] [Full Text] [Related]
6. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017 [Abstract] [Full Text] [Related]
7. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA. Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290 [Abstract] [Full Text] [Related]
8. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A. Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088 [Abstract] [Full Text] [Related]
10. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P. Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628 [Abstract] [Full Text] [Related]
13. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Thiel A, Heinonen M, Kantonen J, Gylling A, Lahtinen L, Korhonen M, Kytölä S, Mecklin JP, Orpana A, Peltomäki P, Ristimäki A. Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522 [Abstract] [Full Text] [Related]
14. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Estrella JS, Tetzlaff MT, Bassett RL, Patel KP, Williams MD, Curry JL, Rashid A, Hamilton SR, Broaddus RR. Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153 [Abstract] [Full Text] [Related]
18. BRAF V600E immunohistochemistry demonstrates that some sessile serrated lesions with adenomatous dysplasia may represent collision lesions. Bettington M, Liu C, Gill A, Walker N, Leggett B, Whitehall V, Rosty C. Histopathology; 2019 Jul; 75(1):81-87. PubMed ID: 30825335 [Abstract] [Full Text] [Related]